{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:16:42Z","timestamp":1791429402336,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T00:00:00Z","timestamp":1392854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10549-014-2878-x","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T19:44:25Z","timestamp":1392839065000},"page":"263-272","source":"Crossref","is-referenced-by-count":59,"title":["Therapeutic potential of the dual EGFR\/HER2\u00a0inhibitor AZD8931 in circumventing endocrine resistance"],"prefix":"10.1007","volume":"144","author":[{"given":"Gladys","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmistha","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Klinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Kent","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mothaffar F.","family":"Rimawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,20]]},"reference":[{"issue":"10","key":"2878_CR1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","volume":"2","author":"GM Clark","year":"1984","unstructured":"Clark GM, Osborne CK, McGuire WL (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2(10):1102\u20131109","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2878_CR2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6601629","volume":"90","author":"CK Osborne","year":"2004","unstructured":"Osborne CK, Wakeling A, Nicholson RI (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S2\u2013S6","journal-title":"Br J Cancer"},{"issue":"2","key":"2878_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02966945","volume":"2","author":"GM Clark","year":"1995","unstructured":"Clark GM (1995) Prognostic and predictive factors for breast cancer. Breast Cancer 2(2):79\u201389","journal-title":"Breast Cancer"},{"key":"2878_CR4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233\u2013247","journal-title":"Annu Rev Med"},{"issue":"3","key":"2878_CR5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","volume":"68","author":"S Massarweh","year":"2008","unstructured":"Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68(3):826\u2013833","journal-title":"Cancer Res"},{"issue":"5","key":"2878_CR6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/ERC-10-0046","volume":"18","author":"SC Drury","year":"2011","unstructured":"Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z, Habben K et al (2011) Changes in breast cancer biomarkers in the IGF1R\/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 18(5):565\u2013577","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"2878_CR7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00280-005-0108-2","volume":"56","author":"R Schiff","year":"2005","unstructured":"Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK (2005) Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(Suppl 1):10\u201320","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2\u20135","key":"2878_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jsbmb.2004.12.006","volume":"93","author":"RI Nicholson","year":"2005","unstructured":"Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM (2005) Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93(2\u20135):257\u2013262","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"2878_CR9","first-page":"S99","volume":"12","author":"JM Gee","year":"2005","unstructured":"Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI (2005) Epidermal growth factor receptor\/HER2\/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1):S99\u2013S111","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2878_CR10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","volume":"95","author":"CK Osborne","year":"2003","unstructured":"Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353\u2013361","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2878_CR11","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1128\/MCB.20.14.5041-5047.2000","volume":"20","author":"Font Mora de","year":"2000","unstructured":"de Mora Font (2000) J, Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20(14):5041\u20135047","journal-title":"Mol Cell Biol"},{"issue":"18","key":"2878_CR12","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1158\/0008-5472.CAN-08-1404","volume":"68","author":"CJ Creighton","year":"2008","unstructured":"Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18):7493\u20137501","journal-title":"Cancer Res"},{"issue":"2","key":"2878_CR13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127\u2013137","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2878_CR14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","volume":"15","author":"D Karunagaran","year":"1996","unstructured":"Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15(2):254\u2013264","journal-title":"EMBO J"},{"issue":"1","key":"2878_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","volume":"284","author":"RN Jorissen","year":"2003","unstructured":"Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284(1):31\u201353","journal-title":"Exp Cell Res"},{"issue":"8","key":"2878_CR16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","volume":"12","author":"Y Yarden","year":"2012","unstructured":"Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12(8):553\u2013563","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2878_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","volume":"21","author":"NE Hynes","year":"2009","unstructured":"Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2):177\u2013184","journal-title":"Curr Opin Cell Biol"},{"issue":"7","key":"2878_CR18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","volume":"26","author":"M Dowsett","year":"2008","unstructured":"Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26(7):1059\u20131065","journal-title":"J Clin Oncol"},{"issue":"1","key":"2878_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(07)70386-8","volume":"9","author":"BB Rasmussen","year":"2008","unstructured":"Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell\u2019Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Mery E, Lacroix-Triki M et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9(1):23\u201328","journal-title":"Lancet Oncol"},{"issue":"12","key":"2878_CR20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926\u2013935","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2878_CR21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1210\/en.2002-220620","volume":"144","author":"JM Knowlden","year":"2003","unstructured":"Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI (2003) Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3):1032\u20131044","journal-title":"Endocrinology"},{"issue":"14","key":"2878_CR22","first-page":"3350","volume":"56","author":"CK Tang","year":"1996","unstructured":"Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R (1996) Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56(14):3350\u20133358","journal-title":"Cancer Res"},{"issue":"1 Pt 2","key":"2878_CR23","doi-asserted-by":"crossref","first-page":"331S","DOI":"10.1158\/1078-0432.CCR-031212","volume":"10","author":"R Schiff","year":"2004","unstructured":"Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10(1 Pt 2):331S\u2013336S","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7","key":"2878_CR24","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","volume":"16","author":"SR Johnston","year":"2010","unstructured":"Johnston SR (2010) New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16(7):1979\u20131987","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2878_CR25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","volume":"16","author":"M Cristofanilli","year":"2010","unstructured":"Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S et al (2010) Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16(6):1904\u20131914","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2878_CR26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-10-1869","volume":"17","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK et al (2011) Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 17(5):1147\u20131159","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2878_CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1634\/theoncologist.2009-0240","volume":"15","author":"LS Schwartzberg","year":"2010","unstructured":"Schwartzberg LS, Franco SX, Florance A, O\u2019Rourke L, Maltzman J, Johnston S (2010) Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 15(2):122\u2013129","journal-title":"Oncologist"},{"key":"2878_CR28","doi-asserted-by":"crossref","unstructured":"Finn RS, Press MF, Dering J, O\u2019Rourke L, Florance A, Ellis C, Martin AM, Johnston S (2014) Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 20(3):736\u2013743","DOI":"10.1158\/1078-0432.CCR-13-1260"},{"issue":"19","key":"2878_CR29","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1101\/gad.1944810","volume":"24","author":"M Lupien","year":"2010","unstructured":"Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS et al (2010) Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 24(19):2219\u20132227","journal-title":"Genes Dev"},{"issue":"5","key":"2878_CR30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-09-3223","volume":"16","author":"IA Mayer","year":"2010","unstructured":"Mayer IA, Arteaga CL (2010) Does lapatinib work against HER2-negative breast cancers? Clin Cancer Res 16(5):1355\u20131357","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2878_CR31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-11-0820","volume":"11","author":"CF McDonagh","year":"2012","unstructured":"McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S et al (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 11(3):582\u2013593","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2878_CR32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-09-2353","volume":"16","author":"DM Hickinson","year":"2010","unstructured":"Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R et al (2010) AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 16(4):1159\u20131169","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2878_CR33","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr3067","volume":"13","author":"YC Wang","year":"2011","unstructured":"Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL et al (2011) Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2013role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13(6):R121","journal-title":"Breast Cancer Res"},{"issue":"20","key":"2878_CR34","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/jnci\/83.20.1477","volume":"83","author":"CK Osborne","year":"1991","unstructured":"Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83(20):1477\u20131482","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2878_CR35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1593\/tlo.11127","volume":"4","author":"A Emde","year":"2011","unstructured":"Emde A, Mahlknecht G, Maslak K, Ribba B, Sela M, Possinger K, Yarden Y (2011) Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance. Transl Oncol 4(5):293\u2013300","journal-title":"Transl Oncol"},{"issue":"2","key":"2878_CR36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-005-9070-2","volume":"96","author":"DJ Britton","year":"2006","unstructured":"Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI (2006) Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96(2):131\u2013146","journal-title":"Breast Cancer Res Treat"},{"issue":"1\u20135","key":"2878_CR37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jsbmb.2007.05.019","volume":"106","author":"SR Johnston","year":"2007","unstructured":"Johnston SR, Martin LA, Leary A, Head J, Dowsett M (2007) Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 106(1\u20135):180\u2013186","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2 Pt 2","key":"2878_CR38","doi-asserted-by":"crossref","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","volume":"11","author":"CK Osborne","year":"2005","unstructured":"Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(2 Pt 2):865s\u2013870s","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2878_CR39","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-09-1764","volume":"16","author":"AF Leary","year":"2010","unstructured":"Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR (2010) Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 16(5):1486\u20131497","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2878_CR40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/0008-5472.18.65.1","volume":"65","author":"I Chu","year":"2005","unstructured":"Chu I, Blackwell K, Chen S, Slingerland J (2005) The dual ErbB1\/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65(1):18\u201325","journal-title":"Cancer Res"},{"issue":"33","key":"2878_CR41","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(33):5538\u20135546","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2878_CR42","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6","volume":"89","author":"A Howell","year":"2000","unstructured":"Howell A, Osborne CK, Morris C, Wakeling AE (2000) ICI 182,780 (Faslodex): development of a novel, \u201cpure\u201d antiestrogen. Cancer 89(4):817\u2013825","journal-title":"Cancer"},{"key":"2878_CR43","doi-asserted-by":"crossref","unstructured":"Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, S\u00f8rensen BS, Lykkesfeldt AE\u00a0(2014) T47D breast cancer cells switch from ER\/HER to HER\/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett 344(1):90\u2013100","DOI":"10.1016\/j.canlet.2013.10.014"},{"key":"2878_CR44","unstructured":"Gwin W, Liu L, Zhao S, Xia W, Spector N (2012) The impact of the heregulin-HER receptor signaling axis on response to HER tyrosine kinase inhibitors. Cancer Res 72(24Suppl):Abstract nr P4-08-03"},{"issue":"4","key":"2878_CR45","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/bcr1754","volume":"9","author":"IR Hutcheson","year":"2007","unstructured":"Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI (2007) Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 9(4):R50","journal-title":"Breast Cancer Res"},{"key":"2878_CR46","doi-asserted-by":"crossref","unstructured":"Johnston SRD (2013) Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J Clin Oncol 31(suppl; abstr 531)","DOI":"10.1200\/jco.2013.31.15_suppl.531"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2878-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-2878-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2878-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T15:53:53Z","timestamp":1689004433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-2878-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["2878"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-2878-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}